cAMPfield Launches With $180M to Advance Oral IBD Therapy
SAN DIEGO, Calif., June 20, 2026 cAMPfield Therapeutics has officially emerged from stealth with a $180 million Series A...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO, Calif., June 20, 2026 cAMPfield Therapeutics has officially emerged from stealth with a $180 million Series A...
SEATTLE, June 17, 2026 Vedana Therapeutics has officially emerged from stealth with $46 million in Series A financing to...
SPRING HOUSE, Pa., Feb. 4, 2026 — Clinical-stage biotechnology company Third Arc Bio announced the closing of a $52...
Boulder, Colorado, January 20, 2026 — Think Bioscience, a privately held biotechnology company focused on unlocking historically “undruggable” drug...
